Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
Find a Doctor
Find a doctor at The Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center or Johns Hopkins Community Physicians.
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Biologic Targeted Therapy
In recent years clinical trials have been conducted to evaluate the effectiveness of new drugs that alter the behavior of the breast cancer cell. These drugs are referred to as targeted therapy or biologic targeted therapy.
During the clinical trial, the pathologist performs a special prognostic factor called HER2neu receptor on the invasive breast cancer cells. This receptor stands for human epidermal growth receptor 2. It is a gene that helps control how cells grow, divide and repair themselves. The HER2 gene (not to be confused with BRCA 1 or 2 genes) directs the production of a special protein. This gene is designed to help the breast cell grow normally. However, if there are too many copies of the gene within the cell, the breast cells then have the ability to turn into a breast cancer cell. Those breast cancers that are HER2neu positive are considered more aggressive.
A special test referred to as FISH (Fluorescence in situ Hybridization) is used by the pathologist to determine if the breast cancer cells are HER2neu positive or negative. If positive, a patient may be advised to take targeted biologic therapy.
Three types of targeted biologic therapy:
- Herceptin® (trastuzumab) – This drug binds to the HER2 receptors on the surface of the cell to prevent it from overproducing the protein that is causing the problem. It can also limit the breast cancer cell’s ability to grow and subdivide. Herceptin works in multiple ways: to block tumor cell growth; to try to target the cell for destruction by the immune system; or it may work with chemotherapy to destroy the HER2neu positive cancer cells. This drug can be given alone or with specific chemotherapy agents. It is not unusual for a patient to be advised to take this drug for a year. It is given intravenously.
- Tykerb® (lapatinib) – It can be used when Herceptin is no longer working, and it also may be considered an option for women with metastatic disease to the brain since it crosses the blood-brain barrier. It is given in pill form.
- Avastin® – Additional research is currently being done to help determine the optimum time to be using this drug. It is often used in the presence of metastatic disease.